Global IBS-C Drugs Market Size, Status and Forecast 2020-2026

1 Report Overview

• 1.1 Study Scope
• 1.2 Key Market Segments
• 1.3 Players Covered: Ranking by IBS-C Drugs Revenue
• 1.4 Market by Type
  • 1.4.1 Global IBS-C Drugs Market Size Growth Rate by Type: 2020 VS 2026
  • 1.4.2 Linaclotide
  • 1.4.3 Lubiprostone
  • 1.4.4 Osmotic Laxatives
  • 1.4.5 Stimulant Laxatives
  • 1.4.6 Other
• 1.5 Market by Application
  • 1.5.1 Global IBS-C Drugs Market Share by Application: 2020 VS 2026
  • 1.5.2 Hospital Pharmacies
  • 1.5.3 Retail Pharmacies
  • 1.5.4 Online Pharmacies
• 1.6 Study Objectives
• 1.7 Years Considered

2 Global Growth Trends

• 2.1 Global IBS-C Drugs Market Perspective (2015-2026)
• 2.2 Global IBS-C Drugs Growth Trends by Regions
  • 2.2.1 IBS-C Drugs Market Size by Regions: 2015 VS 2020 VS 2026
  • 2.2.2 IBS-C Drugs Historic Market Share by Regions (2015-2020)
  • 2.2.3 IBS-C Drugs Forecasted Market Size by Regions (2021-2026)
• 2.3 Industry Trends and Growth Strategy
  • 2.3.1 Market Top Trends
  • 2.3.2 Market Drivers
  • 2.3.3 Market Challenges
  • 2.3.4 Porter’s Five Forces Analysis
  • 2.3.5 IBS-C Drugs Market Growth Strategy
  • 2.3.6 Primary Interviews with Key IBS-C Drugs Players (Opinion Leaders)

3 Competition Landscape by Key Players

• 3.1 Global Top IBS-C Drugs Players by Market Size
  • 3.1.1 Global Top IBS-C Drugs Players by Revenue (2015-2020)
  • 3.1.2 Global IBS-C Drugs Revenue Market Share by Players (2015-2020)
  • 3.1.3 Global IBS-C Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
• 3.2 Global IBS-C Drugs Market Concentration Ratio
  • 3.2.1 Global IBS-C Drugs Market Concentration Ratio (CR5 and HHI)
  • 3.2.2 Global Top 10 and Top 5 Companies by IBS-C Drugs Revenue in 2019
• 3.3 IBS-C Drugs Key Players Head office and Area Served
• 3.4 Key Players IBS-C Drugs Product Solution and Service
• 3.5 Date of Enter into IBS-C Drugs Market
• 3.6 Mergers & Acquisitions, Expansion Plans

4 Market Size by Type (2015-2026)

• 4.1 Global IBS-C Drugs Historic Market Size by Type (2015-2020)
• 4.2 Global IBS-C Drugs Forecasted Market Size by Type (2021-2026)

5 Market Size by Application (2015-2026)

• 5.1 Global IBS-C Drugs Market Size by Application (2015-2020)
• 5.2 Global IBS-C Drugs Forecasted Market Size by Application (2021-2026)

6 North America

• 6.1 North America IBS-C Drugs Market Size (2015-2020)
• 6.2 IBS-C Drugs Key Players in North America (2019-2020)
• 6.3 North America IBS-C Drugs Market Size by Type (2015-2020)
• 6.4 North America IBS-C Drugs Market Size by Application (2015-2020)

7 Europe

• 7.1 Europe IBS-C Drugs Market Size (2015-2020)
• 7.2 IBS-C Drugs Key Players in Europe (2019-2020)
• 7.3 Europe IBS-C Drugs Market Size by Type (2015-2020)
• 7.4 Europe IBS-C Drugs Market Size by Application (2015-2020)

8 China

• 8.1 China IBS-C Drugs Market Size (2015-2020)
• 8.2 IBS-C Drugs Key Players in China (2019-2020)
• 8.3 China IBS-C Drugs Market Size by Type (2015-2020)
• 8.4 China IBS-C Drugs Market Size by Application (2015-2020)

9 Japan

• 9.1 Japan IBS-C Drugs Market Size (2015-2020)
• 9.2 IBS-C Drugs Key Players in Japan (2019-2020)
• 9.3 Japan IBS-C Drugs Market Size by Type (2015-2020)
• 9.4 Japan IBS-C Drugs Market Size by Application (2015-2020)

10 Southeast Asia

• 10.1 Southeast Asia IBS-C Drugs Market Size (2015-2020)
• 10.2 IBS-C Drugs Key Players in Southeast Asia (2019-2020)
• 10.3 Southeast Asia IBS-C Drugs Market Size by Type (2015-2020)
• 10.4 Southeast Asia IBS-C Drugs Market Size by Application (2015-2020)

11 India

• 11.1 India IBS-C Drugs Market Size (2015-2020)
• 11.2 IBS-C Drugs Key Players in India (2019-2020)
• 11.3 India IBS-C Drugs Market Size by Type (2015-2020)
• 11.4 India IBS-C Drugs Market Size by Application (2015-2020)

12 Central & South America

• 12.1 Central & South America IBS-C Drugs Market Size (2015-2020)
• 12.2 IBS-C Drugs Key Players in Central & South America (2019-2020)
• 12.3 Central & South America IBS-C Drugs Market Size by Type (2015-2020)
• 12.4 Central & South America IBS-C Drugs Market Size by Application (2015-2020)

13 Key Players Profiles

• 13.1 Catalent Pharmaceuticals Solutions
  • 13.1.1 Catalent Pharmaceuticals Solutions Company Details
  • 13.1.2 Catalent Pharmaceuticals Solutions Business Overview
  • 13.1.3 Catalent Pharmaceuticals Solutions IBS-C Drugs Introduction
  • 13.1.4 Catalent Pharmaceuticals Solutions Revenue in IBS-C Drugs Business (2015-2020))
  • 13.1.5 Catalent Pharmaceuticals Solutions Recent Development
• 13.2 Nestle
  • 13.2.1 Nestle Company Details
  • 13.2.2 Nestle Business Overview
  • 13.2.3 Nestle IBS-C Drugs Introduction
  • 13.2.4 Nestle Revenue in IBS-C Drugs Business (2015-2020)
  • 13.2.5 Nestle Recent Development
• 13.3 Abbott Laboratories
  • 13.3.1 Abbott Laboratories Company Details
  • 13.3.2 Abbott Laboratories Business Overview
  • 13.3.3 Abbott Laboratories IBS-C Drugs Introduction
  • 13.3.4 Abbott Laboratories Revenue in IBS-C Drugs Business (2015-2020)
  • 13.3.5 Abbott Laboratories Recent Development
• 13.4 Synergy Pharmaceuticals
  • 13.4.1 Synergy Pharmaceuticals Company Details
  • 13.4.2 Synergy Pharmaceuticals Business Overview
  • 13.4.3 Synergy Pharmaceuticals IBS-C Drugs Introduction
  • 13.4.4 Synergy Pharmaceuticals Revenue in IBS-C Drugs Business (2015-2020)
  • 13.4.5 Synergy Pharmaceuticals Recent Development
• 13.5 Sucampo Pharmaceuticals
  • 13.5.1 Sucampo Pharmaceuticals Company Details
  • 13.5.2 Sucampo Pharmaceuticals Business Overview
  • 13.5.3 Sucampo Pharmaceuticals IBS-C Drugs Introduction
  • 13.5.4 Sucampo Pharmaceuticals Revenue in IBS-C Drugs Business (2015-2020)
  • 13.5.5 Sucampo Pharmaceuticals Recent Development
• 13.6 Novartis Pharma Ag
  • 13.6.1 Novartis Pharma Ag Company Details
  • 13.6.2 Novartis Pharma Ag Business Overview
  • 13.6.3 Novartis Pharma Ag IBS-C Drugs Introduction
  • 13.6.4 Novartis Pharma Ag Revenue in IBS-C Drugs Business (2015-2020)
  • 13.6.5 Novartis Pharma Ag Recent Development
• 13.7 Astellas Pharmaceuticals
  • 13.7.1 Astellas Pharmaceuticals Company Details
  • 13.7.2 Astellas Pharmaceuticals Business Overview
  • 13.7.3 Astellas Pharmaceuticals IBS-C Drugs Introduction
  • 13.7.4 Astellas Pharmaceuticals Revenue in IBS-C Drugs Business (2015-2020)
  • 13.7.5 Astellas Pharmaceuticals Recent Development
• 13.8 Ardelyx, Inc
  • 13.8.1 Ardelyx, Inc Company Details
  • 13.8.2 Ardelyx, Inc Business Overview
  • 13.8.3 Ardelyx, Inc IBS-C Drugs Introduction
  • 13.8.4 Ardelyx, Inc Revenue in IBS-C Drugs Business (2015-2020)
  • 13.8.5 Ardelyx, Inc Recent Development
• 13.9 Synthetic Biologics, Inc
  • 13.9.1 Synthetic Biologics, Inc Company Details
  • 13.9.2 Synthetic Biologics, Inc Business Overview
  • 13.9.3 Synthetic Biologics, Inc IBS-C Drugs Introduction
  • 13.9.4 Synthetic Biologics, Inc Revenue in IBS-C Drugs Business (2015-2020)
  • 13.9.5 Synthetic Biologics, Inc Recent Development
• 13.10 Teva Pharmaceutical Industries
  • 13.10.1 Teva Pharmaceutical Industries Company Details
  • 13.10.2 Teva Pharmaceutical Industries Business Overview
  • 13.10.3 Teva Pharmaceutical Industries IBS-C Drugs Introduction
  • 13.10.4 Teva Pharmaceutical Industries Revenue in IBS-C Drugs Business (2015-2020)
  • 13.10.5 Teva Pharmaceutical Industries Recent Development
• 13.11 Bama-Geve, SLU
  • 10.11.1 Bama-Geve, SLU Company Details
  • 10.11.2 Bama-Geve, SLU Business Overview
  • 10.11.3 Bama-Geve, SLU IBS-C Drugs Introduction
  • 10.11.4 Bama-Geve, SLU Revenue in IBS-C Drugs Business (2015-2020)
  • 10.11.5 Bama-Geve, SLU Recent Development
• 13.12 Ferring BV
  • 10.12.1 Ferring BV Company Details
  • 10.12.2 Ferring BV Business Overview
  • 10.12.3 Ferring BV IBS-C Drugs Introduction
  • 10.12.4 Ferring BV Revenue in IBS-C Drugs Business (2015-2020)
  • 10.12.5 Ferring BV Recent Development
• 13.13 Ironwood Pharmaceuticals, Inc
  • 10.13.1 Ironwood Pharmaceuticals, Inc Company Details
  • 10.13.2 Ironwood Pharmaceuticals, Inc Business Overview
  • 10.13.3 Ironwood Pharmaceuticals, Inc IBS-C Drugs Introduction
  • 10.13.4 Ironwood Pharmaceuticals, Inc Revenue in IBS-C Drugs Business (2015-2020)
  • 10.13.5 Ironwood Pharmaceuticals, Inc Recent Development
• 13.14 Salix Pharmaceuticals Ltd
  • 10.14.1 Salix Pharmaceuticals Ltd Company Details
  • 10.14.2 Salix Pharmaceuticals Ltd Business Overview
  • 10.14.3 Salix Pharmaceuticals Ltd IBS-C Drugs Introduction
  • 10.14.4 Salix Pharmaceuticals Ltd Revenue in IBS-C Drugs Business (2015-2020)
  • 10.14.5 Salix Pharmaceuticals Ltd Recent Development
• 13.15 Norgine B.V
  • 10.15.1 Norgine B.V Company Details
  • 10.15.2 Norgine B.V Business Overview
  • 10.15.3 Norgine B.V IBS-C Drugs Introduction
  • 10.15.4 Norgine B.V Revenue in IBS-C Drugs Business (2015-2020)
  • 10.15.5 Norgine B.V Recent Development
• 13.16 Prometheus Laboratories Inc
  • 10.16.1 Prometheus Laboratories Inc Company Details
  • 10.16.2 Prometheus Laboratories Inc Business Overview
  • 10.16.3 Prometheus Laboratories Inc IBS-C Drugs Introduction
  • 10.16.4 Prometheus Laboratories Inc Revenue in IBS-C Drugs Business (2015-2020)
  • 10.16.5 Prometheus Laboratories Inc Recent Development
• 13.17 Actavis Nordic A/S
  • 10.17.1 Actavis Nordic A/S Company Details
  • 10.17.2 Actavis Nordic A/S Business Overview
  • 10.17.3 Actavis Nordic A/S IBS-C Drugs Introduction
  • 10.17.4 Actavis Nordic A/S Revenue in IBS-C Drugs Business (2015-2020)
  • 10.17.5 Actavis Nordic A/S Recent Development
• 13.18 Albireo Pharma Inc
  • 10.18.1 Albireo Pharma Inc Company Details
  • 10.18.2 Albireo Pharma Inc Business Overview
  • 10.18.3 Albireo Pharma Inc IBS-C Drugs Introduction
  • 10.18.4 Albireo Pharma Inc Revenue in IBS-C Drugs Business (2015-2020)
  • 10.18.5 Albireo Pharma Inc Recent Development
• 13.19 Yuhan Corp
  • 10.19.1 Yuhan Corp Company Details
  • 10.19.2 Yuhan Corp Business Overview
  • 10.19.3 Yuhan Corp IBS-C Drugs Introduction
  • 10.19.4 Yuhan Corp Revenue in IBS-C Drugs Business (2015-2020)
  • 10.19.5 Yuhan Corp Recent Development
• 13.20 Astrazeneca Plc
  • 10.20.1 Astrazeneca Plc Company Details
  • 10.20.2 Astrazeneca Plc Business Overview
  • 10.20.3 Astrazeneca Plc IBS-C Drugs Introduction
  • 10.20.4 Astrazeneca Plc Revenue in IBS-C Drugs Business (2015-2020)
  • 10.20.5 Astrazeneca Plc Recent Development
• 13.21 The Menarini Group
  • 10.21.1 The Menarini Group Company Details
  • 10.21.2 The Menarini Group Business Overview
  • 10.21.3 The Menarini Group IBS-C Drugs Introduction
  • 10.21.4 The Menarini Group Revenue in IBS-C Drugs Business (2015-2020)
  • 10.21.5 The Menarini Group Recent Development
• 13.22 Ono Pharmaceutical Co., Ltd
  • 10.22.1 Ono Pharmaceutical Co., Ltd Company Details
  • 10.22.2 Ono Pharmaceutical Co., Ltd Business Overview
  • 10.22.3 Ono Pharmaceutical Co., Ltd IBS-C Drugs Introduction
  • 10.22.4 Ono Pharmaceutical Co., Ltd Revenue in IBS-C Drugs Business (2015-2020)
  • 10.22.5 Ono Pharmaceutical Co., Ltd Recent Development

14 Analyst's Viewpoints/Conclusions

15 Appendix

• 15.1 Research Methodology
  • 15.1.1 Methodology/Research Approach
  • 15.1.2 Data Source
• 15.2 Disclaimer